Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
The prostaglandin E1 analog misoprostol reduces symptoms and microvascular arteriovenous shunting in erythromelalgia-a double-blind, crossover, placebo-compared study.
Rikshospitalet University Hospital.
Linköpings universitet.
Karlstad University.ORCID iD: 0000-0002-3356-9952
Ulleval University Hospital.
2004 (English)In: Journal of Investigative Dermatology, ISSN 0022-202X, E-ISSN 1523-1747, Vol. 122, no 3, p. 587-93Article in journal (Refereed) Published
Abstract [en]

Based on previous experience with parenteral prostanoids, we studied the effect of misoprostol treatment, an orally administered prostaglandin E1 analog, in patients with erythromelalgia. Treatment with placebo was followed by treatment with misoprostol (0.4-0.8 mg per d), both for 6 wk. The patients (n=21) and a study nurse who administered the trial were blinded. The endpoints were change in pain and need for cooling and global assessment of the treatment. Following central body heat provocation, global skin perfusion, capillary morphology, and change in pain were also recorded before and after each treatment period. Results were compared with data from healthy control subjects (n=11) that did not undergo treatment. Clinical safety and tolerability evaluation included physical examinations, clinical laboratory tests, and monitoring of adverse events. All clinical outcome measures were significantly better after treatment with misoprostol (p<0.01) as compared with placebo treatment and after a 3- mo follow-up without treatment. The heat-induced increase in global perfusion after misoprostol treatment was similar to the control group and significantly lower when compared with baseline (p<0.01) and placebo treatment (p<0.05), respectively. This study demonstrates that misoprostol is clinically superior to placebo in patients with erythromelalgia. The results of the perfusion studies may imply that the mechanism of action of the beneficial effect of misoprostol is reduced microvascular arteriovenous shunting in affected skin.

Place, publisher, year, edition, pages
2004. Vol. 122, no 3, p. 587-93
National Category
Computer Vision and Robotics (Autonomous Systems)
Research subject
Biomedical Laboratory Science
Identifiers
URN: urn:nbn:se:kau:diva-3195DOI: 10.1111/j.0022-202X.2004.22339.xPubMedID: 15086539OAI: oai:DiVA.org:kau-3195DiVA, id: diva2:128368
Available from: 2008-12-16 Created: 2008-12-16 Last updated: 2018-01-13Bibliographically approved

Open Access in DiVA

fulltext(350 kB)690 downloads
File information
File name FULLTEXT01.pdfFile size 350 kBChecksum SHA-512
ff9d8760ba48a752437a811b346a34cba38acd7cc2da578da8b01b64ea0b88681f39eb94eda865b33532794979ab4eb86ede07dff5f95f1ddf99aff80277ffce
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMedhttp://www.nature.com/jid/journal/v122/n3/full/5602219a.html

Authority records BETA

Asker, Claes L

Search in DiVA

By author/editor
Asker, Claes L
By organisation
Karlstad University
In the same journal
Journal of Investigative Dermatology
Computer Vision and Robotics (Autonomous Systems)

Search outside of DiVA

GoogleGoogle Scholar
Total: 690 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 349 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf